New Delhi, India: Zydus Cadila, a pharmaceutical company, announced on Tuesday that it has gotten conditional approval from the US Food and Drug Administration to market Lenalidomide Capsules, which are used to treat certain types of malignancies.
The US Food and Drug Administration (USFDA) has given the company provisional approval to market Lenalidomide Capsules in the strengths of 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg.
Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS).
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad, the company said in a statement.
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…